link.springer.com

PSK may suppress CD57+ T cells to improve survival of advanced gastric cancer patients - International Journal of Clinical Oncology

  • ️Baba, Hideo
  • ️Sat Mar 13 2010

  • Tsukagoshi S, Hashimoto Y, Fujii G et al (1984) Krestin (PSK). Cancer Treat Rev 11:131–155

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi H, Matsunaga K, Oguchi Y (1995) Anti-metastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 4:275–281

    CAS  PubMed  Google Scholar 

  • Nakazato H, Koike A, Saji S et al (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122–1126

    Article  CAS  PubMed  Google Scholar 

  • Mitomi T, Tsuchiya S, Iijima N et al (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35:123–130

    Article  CAS  PubMed  Google Scholar 

  • Ohwada S, Ikeya T, Yokomori T et al (2004) Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomized controlled study. Br J Cancer 90:1003–1010

    Article  CAS  PubMed  Google Scholar 

  • Hirose K, Zachariae CO, Oppenheim JJ et al (1990) Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 9:475–483

    CAS  PubMed  Google Scholar 

  • Abe Y, Miyake M, Horiuchi A et al (1990) Induction of cytokines by polysaccharide K in the peripheral blood mononuclear cell culture. J Clin Exp Med 152:617

    CAS  Google Scholar 

  • Kanazawa M, Mori Y, Yoshihara K et al (2004) Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocyte. Immunol Lett 91:229–238

    Article  CAS  PubMed  Google Scholar 

  • Harada M, Matsunaga K, Oguchi Y et al (1995) The involvement of transforming growth factor beta in the impaired antitumor T cell response at the gut-associated lymphoid tissue (GALT). Cancer Res 55:6146–6151

    CAS  PubMed  Google Scholar 

  • Van der Pouw Kraan TC, Beoije LC, Smeenk RJ et al (1995) Prostaglandin E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181:775–779

    Article  PubMed  Google Scholar 

  • Matsuda JL, Gapin L, Fazilleau N et al (2001) Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor repertoire and small clone size. Proc Natl Acad Sci USA 98:12636–12641

    Article  CAS  PubMed  Google Scholar 

  • Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277–348

    Article  CAS  PubMed  Google Scholar 

  • Takii Y, Hashimoto S, Iiai T et al (1994) Increase in the proportion of granulated CD56+ T cells in patients with malignancy. Clin Exp Immunol 97:522–527

    CAS  PubMed  Google Scholar 

  • Okada T, Iiai T, Kawachi Y et al (1995) Origin of CD8+ CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159–166

    Article  CAS  PubMed  Google Scholar 

  • Koyama S, Ebihara T, Fukao K (1992) Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 118:609–614

    Article  CAS  PubMed  Google Scholar 

  • Karimine N, Nanbara S, Arinaga S et al (1994) Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. J Surg Oncol 55:179–185

    Article  CAS  PubMed  Google Scholar 

  • Groux H, O’Garra A, Bigler M (1997) A CD4+ T cells subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (Lond) 389:737–742

    Article  CAS  Google Scholar 

  • Thomason AM, Shevach EM (1998) CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287–296

    Article  Google Scholar 

  • Thomason AM, Shevach EM (2000) Suppressor effector function of CD4+ 25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164:183–190

    Google Scholar 

  • Takahashi T, Tagami T, Yamazaki S et al (2000) Immunologic self tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303–310

    Article  CAS  PubMed  Google Scholar 

  • Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455–458

    Article  CAS  PubMed  Google Scholar 

  • Shevach EM (2001) Certified professionals: CD4+ CD25+ suppressor T cells. J Exp Med 193:F41–F46

    Article  CAS  PubMed  Google Scholar 

  • Azuma T, Takahashi T, Kinusato A et al (2003) Human CD4+ 25+ regulatory T cells suppress NKT cell functions. Cancer Res 63:4516–4520

    CAS  PubMed  Google Scholar 

  • Ichihara F, Kono K, Takahashi A et al (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patient with gastric and esophageal cancers. Clin Cancer Res 9:4404–4408

    PubMed  Google Scholar 

  • Wolf AM, Wolf D, Steurer M et al (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612

    PubMed  Google Scholar 

  • Sasada T, Kimura M, Yoshida Y et al (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer (Phila) 98:1089–1099

    Article  Google Scholar 

  • Picker LJ, Singh MK, Zdraveski Z et al (1995) Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86:1408–1419

    CAS  PubMed  Google Scholar 

  • Akagi J, Baba H (2008) Prognostic value of CD57+ T lymphocytes in the peripheral blood of advanced gastric cancer patients. Int J Clin Oncol (in press)

  • Oba K, Teramukai S, Kobayashi M et al (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905–911

    Article  CAS  PubMed  Google Scholar 

  • Wajchman HJ, Pierce CW, Varma VA et al (2004) Ex vivo expansion of CD8+CD56+ and CD8+CD56− natural killer T cells specific for MUC1 mucin. Cancer Res 64:1171–1180

    Article  CAS  PubMed  Google Scholar 

  • Baxevanis CN, Gritzapis AD, Tsitsilois OE et al (2002) HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 20:864–872

    Article  CAS  Google Scholar 

  • Izquierdo M, Balboa MA, Fernandez-Ranada JM et al (1990) Relation between the increase of circulating CD3+CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation. Clin Exp Immunol 82:145–150

    Article  CAS  PubMed  Google Scholar 

  • Hilbe W, Eisterer W, Schmid C (1994) Bone marrow lymphocytes subsets in myelodysplastic syndromes. J Clin Pathol 47:505–507

    Article  CAS  PubMed  Google Scholar 

  • Gorochov G, Debre P, Leblond V et al (1994) Oligoclonal expansion of CD8+CD8+CD57+ T cells with restricted T-cell receptor chain variability after bone marrow transplantation. Blood 83:587–595

    CAS  PubMed  Google Scholar 

  • Fregona I, Guttmann RD, Jean R (1985) HNK-1 + (Leu-7) and other lymphocyte subsets in long-term survivors with renal allotransplants. Transplantation 39:25–29

    CAS  PubMed  Google Scholar 

  • Arai K, Yamamura S, Seki S et al (1998) Increase of CD8+CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role. Clin Exp Immunol 111:345–352

    Article  CAS  PubMed  Google Scholar 

  • Dupuy d’Angeac A, Monier S et al (1993) Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum 36:608–612

    Article  PubMed  Google Scholar 

  • Legac E, Autran B, Merie-Beral H et al (1992) CD4+CD7–CD8+CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood 79:1746–1753

    CAS  PubMed  Google Scholar 

  • Sadat-Sowti B, Debre P, Mollet L et al (1994) An inhibitor of cytotoxic functions produced by CD8+ CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol 24:2882–2888

    Article  CAS  PubMed  Google Scholar 

  • Autran B, Leblond V, Sadat-Sowti B et al (1991) A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood 77:2237–2241

    CAS  PubMed  Google Scholar 

  • Chochi K, Ichikura T, Majaima T et al (2003) The increase of CD8+CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep 20:2443–2448

    Google Scholar 

  • Characiejus D, Pasukoniene V, Kazlauskaite K et al (2002) Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22:3679–3684

    PubMed  Google Scholar 

  • Marinova E, Han S, Zheng B (2007) Germinal center helper T cells are dual functional regulatory cells with suppressive activity to conventional CD4+ T cells. J Immunol 178:5010–5017

    CAS  PubMed  Google Scholar 

  • Alvaro T, Lejeune M, Salvado MT et al (2006) Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma. J Clin Oncol 24:5350–5357

    Article  PubMed  Google Scholar 

  • Mollet L, Sadat-Sowti B, Duntze J et al (1998) CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 10:311–323

    Article  CAS  PubMed  Google Scholar 

  • Frassanito MA, Silvestris F, Cafforio P et al (1998) CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. Br J Haematol 100:469–477

    Article  CAS  PubMed  Google Scholar 

  • Sze DM, Giesajitis G, Brown RD et al (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8 + CD57+CD28– compartment. Blood 98:2817–2827

    Article  CAS  PubMed  Google Scholar